A sliver of hope for head and neck cancer
A small study, presented at ESMO Congress 2018 suggests that the orally administered fibroblast growth factor receptor (FGFR) inhibitor rogaratinib could be beneficial for a subset of patients with head and neck cancer.
Dr. Markus Jörger, Kantonsspital St. Gallen, presenting the collective outcome of two combined phase I trials.
Um das Video zu sehen, müssen Sie sich einloggen oder kostenlos registrieren.
More from this topic: